World leaders at the UN High-Level Meeting on TB have approved a Political Declaration with ambitious new targets for the next five years to advance the global efforts towards ending the TB epidemic.

USAID and PEPFAR announce that they have secured a 30% price reduction on the TB preventive treatment regimen called 3HP, taking the price from $14.25 to $9.99 for a three-month patient course.

Ukraine, Belarus, Azerbaijan and Moldova demand that Johnson & Johnson take urgent action to improve equitable access to bedaquiline in all countries with a high burden of TB.

A sobering new analysis from Treatment Action Group shows that governments failed to meet previous commitments to fund TB research.

Ahead of the UN General Assembly High-Level Meeting on TB, the 1/4/6×24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.

Global Fund, Stop TB Partnership and USAID announce new collaboration with Danaher to reduce price and increase access to Cepheid’s TB test. Five million additional tests can be procured with this lower price.

Results in the fight against HIV, TB and malaria exceed pre-COVID-19 numbers; yet colliding crises keep the world way off track to achieve 2030 targets.

Without action, more than 27 million lives could be lost between now and 2050.

TB is curable but remains the world’s leading infectious disease killer as pharma corporations stand in the way of affordable medical tools.

WHO urges world leaders to commit to progress on pandemic prevention, preparedness and response and to secure health for all, end TB, and reinvigorate SDGs.